PL1818052T3 - Zastosowanie formoterolu w profilaktycznym i/lub terapeutycznym leczeniu wyniszczenia mięśniowego i/lub zespołu wyniszczenia, związanych ze stanami katabolicznymi w przebiegu niektórych chorób, takich jak nowotwory, AIDS, zakażenia, cukrzyca i inne - Google Patents
Zastosowanie formoterolu w profilaktycznym i/lub terapeutycznym leczeniu wyniszczenia mięśniowego i/lub zespołu wyniszczenia, związanych ze stanami katabolicznymi w przebiegu niektórych chorób, takich jak nowotwory, AIDS, zakażenia, cukrzyca i inneInfo
- Publication number
- PL1818052T3 PL1818052T3 PL05763090T PL05763090T PL1818052T3 PL 1818052 T3 PL1818052 T3 PL 1818052T3 PL 05763090 T PL05763090 T PL 05763090T PL 05763090 T PL05763090 T PL 05763090T PL 1818052 T3 PL1818052 T3 PL 1818052T3
- Authority
- PL
- Poland
- Prior art keywords
- formoterol
- prophylactic
- diabetes
- aids
- cancer
- Prior art date
Links
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002848 formoterol Drugs 0.000 title abstract 4
- 208000011580 syndromic disease Diseases 0.000 title abstract 3
- 206010028289 Muscle atrophy Diseases 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000001612 cachectic effect Effects 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 201000000585 muscular atrophy Diseases 0.000 title abstract 2
- 230000000069 prophylactic effect Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 230000001925 catabolic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 2
- 206010007733 Catabolic state Diseases 0.000 abstract 2
- NWLPAIVRIWBEIT-SEPHDYHBSA-N (e)-but-2-enedioic acid;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O NWLPAIVRIWBEIT-SEPHDYHBSA-N 0.000 abstract 1
- 208000009079 Bronchial Spasm Diseases 0.000 abstract 1
- 208000014181 Bronchial disease Diseases 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000003269 anti-cachectic effect Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200401941A ES2245612B1 (es) | 2004-06-29 | 2004-06-29 | Nuevo uso terapeutico del formoterol. |
| PCT/ES2005/000365 WO2006003222A1 (es) | 2004-06-29 | 2005-06-28 | Uso del formoterol en el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o síndrome caquéctico, asociados a estados catabólicos de ciertas enfermedades como cáncer, sida, infecciones, diabetes y otras |
| EP05763090A EP1818052B1 (en) | 2004-06-29 | 2005-06-28 | Use of formoterol in the prophylactic and/or therapeutic treatment of muscle wasting and/or cachectic syndrome which are associated with catabolic conditions of certain diseases, such as cancer, aids, infections, diabetes and others |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1818052T3 true PL1818052T3 (pl) | 2010-04-30 |
Family
ID=35614437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05763090T PL1818052T3 (pl) | 2004-06-29 | 2005-06-28 | Zastosowanie formoterolu w profilaktycznym i/lub terapeutycznym leczeniu wyniszczenia mięśniowego i/lub zespołu wyniszczenia, związanych ze stanami katabolicznymi w przebiegu niektórych chorób, takich jak nowotwory, AIDS, zakażenia, cukrzyca i inne |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1818052B1 (pl) |
| AT (1) | ATE447944T1 (pl) |
| CY (1) | CY1109771T1 (pl) |
| DE (1) | DE602005017659D1 (pl) |
| DK (1) | DK1818052T3 (pl) |
| ES (2) | ES2245612B1 (pl) |
| PL (1) | PL1818052T3 (pl) |
| PT (1) | PT1818052E (pl) |
| WO (1) | WO2006003222A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0625270D0 (en) * | 2006-12-19 | 2007-01-31 | Univ Leicester | Angiogenesis |
| KR101546977B1 (ko) | 2007-04-24 | 2015-08-24 | 아카시아 파마 리미티드 | 근육 손실의 치료에서의 약물 조합 및 그것의 용도 |
| CN117562998A (zh) * | 2023-02-02 | 2024-02-20 | 上海市第十人民医院 | 长效β2AR激动剂在制备治疗癌症药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903995D0 (sv) * | 1999-11-03 | 1999-11-03 | Astra Ab | New combination |
| GB9928311D0 (en) * | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
| WO2002066027A1 (de) * | 2001-02-22 | 2002-08-29 | Universitätsklinikum Charite Medizinische Fakultät Der Humboldt-Universität Zu Berlin, Akademische Verwaltung - Forschung | Mittel zur hemmung von tumorzellen |
-
2004
- 2004-06-29 ES ES200401941A patent/ES2245612B1/es not_active Expired - Fee Related
-
2005
- 2005-06-28 DE DE602005017659T patent/DE602005017659D1/de not_active Expired - Lifetime
- 2005-06-28 WO PCT/ES2005/000365 patent/WO2006003222A1/es not_active Ceased
- 2005-06-28 AT AT05763090T patent/ATE447944T1/de active
- 2005-06-28 DK DK05763090.7T patent/DK1818052T3/da active
- 2005-06-28 PT PT05763090T patent/PT1818052E/pt unknown
- 2005-06-28 EP EP05763090A patent/EP1818052B1/en not_active Expired - Lifetime
- 2005-06-28 PL PL05763090T patent/PL1818052T3/pl unknown
- 2005-06-28 ES ES05763090T patent/ES2336229T3/es not_active Expired - Lifetime
-
2010
- 2010-02-10 CY CY20101100135T patent/CY1109771T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1818052E (pt) | 2010-02-15 |
| ES2245612B1 (es) | 2007-08-16 |
| CY1109771T1 (el) | 2014-09-10 |
| EP1818052A1 (en) | 2007-08-15 |
| ES2245612A1 (es) | 2006-01-01 |
| EP1818052B1 (en) | 2009-11-11 |
| WO2006003222A1 (es) | 2006-01-12 |
| ES2336229T3 (es) | 2010-04-09 |
| ATE447944T1 (de) | 2009-11-15 |
| WO2006003222A9 (es) | 2009-01-15 |
| DK1818052T3 (da) | 2010-03-29 |
| DE602005017659D1 (de) | 2009-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1411932T3 (da) | Kombinationsterapi med substituerede oxazolidinoner | |
| TW200505881A (en) | Tri(cyclo) substituted amide compounds | |
| CY1105082T1 (el) | Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας | |
| MXPA04000647A (es) | Acido 5-aminolevulinico y sus esteres, en combinacion con otro fotosensibilizador, como agentes fotosensibilizadores en fotoquimioterapia y sus usos en el tratamiento de heridas. | |
| WO2003096990A3 (en) | Protein cages for the delivery of medical imaging and therapy | |
| NO20071267L (no) | Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer | |
| EA200601747A1 (ru) | Три(цикло)замещённые амидные соединения | |
| EP1545483A4 (en) | NON-NUCLEOSIDIC INHIBITORS OF INVERSE TRANSCRIPTASES | |
| TW200510343A (en) | Substituted dihydroquinazolines | |
| CY1116464T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| WO2006017188A3 (en) | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients | |
| WO2008045378A3 (en) | Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin | |
| WO2004026260A3 (en) | Prophylactic and therapeutic hiv aptamers | |
| EA200801731A1 (ru) | Составы и способы лечения тробмоцитемии | |
| PT1670489E (pt) | Utilização de xénon com hipotermia para o tratamento de asfixia neonatal | |
| CY1109771T1 (el) | Η χρηση της φορμοτερολης στην προφυλακτικη και/ή θεραπευτικη αντιμετωπιση της μυικης απωλειας και/ή του καχεκτικου συνδρομου τα οποια συνδεονται με τις καταβολικες συνθηκες ορισμενων παθησεων. οπως ο καρκινος, to aids, οι μολυνσεις, ο διαβητης και αλλες | |
| WO2004110373A3 (en) | Therapeutic vaccine compositions for the treatment of type 1 diabetes | |
| MX2008002456A (es) | Uso de ambroxol para el tratamiento de infecciones por rinovirus. | |
| BR0313665A (pt) | Utilização de bupropion para o tratamento da sìndrome das pernas inquietas | |
| IL177169A (en) | Use of n-(2-aryl- propionyl)-sulfonamides for the preparation of medicaments for the treatment of spinal cord injury | |
| DK1416937T3 (da) | Profylaktisk og terapeutisk anvendelse af hydroxysteroider | |
| ZA200703237B (en) | Pharmaceutical agents comprising blood components <10 KDA and their use for prophylaxis and treatment of defects of the immune system | |
| EA200500865A1 (ru) | Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол | |
| WO2007117272A3 (en) | Methods for treatment of hemorrhagic shock and related disorders | |
| HUP0300876A3 (en) | Use of diclofenac for the manufacture of medicament for the topical treatment of burns |